JP2013523844A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523844A5
JP2013523844A5 JP2013504064A JP2013504064A JP2013523844A5 JP 2013523844 A5 JP2013523844 A5 JP 2013523844A5 JP 2013504064 A JP2013504064 A JP 2013504064A JP 2013504064 A JP2013504064 A JP 2013504064A JP 2013523844 A5 JP2013523844 A5 JP 2013523844A5
Authority
JP
Japan
Prior art keywords
ethoxy
pharmaceutical composition
asthma
medicament
copd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013504064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523844A (ja
JP6148618B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2011/000434 external-priority patent/WO2011127538A1/en
Publication of JP2013523844A publication Critical patent/JP2013523844A/ja
Publication of JP2013523844A5 publication Critical patent/JP2013523844A5/ja
Application granted granted Critical
Publication of JP6148618B2 publication Critical patent/JP6148618B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013504064A 2010-04-15 2011-04-14 呼吸器の病態又は疾患の治療のための化合物 Active JP6148618B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2010901601A AU2010901601A0 (en) 2010-04-15 Compound for the treatment of respiratory condition or disease
AU2010901601 2010-04-15
PCT/AU2011/000434 WO2011127538A1 (en) 2010-04-15 2011-04-14 Compound for treatment of respiratory condition or disease

Publications (3)

Publication Number Publication Date
JP2013523844A JP2013523844A (ja) 2013-06-17
JP2013523844A5 true JP2013523844A5 (enExample) 2014-05-29
JP6148618B2 JP6148618B2 (ja) 2017-06-14

Family

ID=44788654

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013504064A Active JP6148618B2 (ja) 2010-04-15 2011-04-14 呼吸器の病態又は疾患の治療のための化合物

Country Status (16)

Country Link
US (1) US20110257192A1 (enExample)
EP (1) EP2558097B1 (enExample)
JP (1) JP6148618B2 (enExample)
KR (1) KR20130106267A (enExample)
CN (2) CN105560245A (enExample)
AU (1) AU2011241478B2 (enExample)
BR (1) BR112012026244A2 (enExample)
CA (1) CA2796207A1 (enExample)
EA (1) EA025224B1 (enExample)
ES (1) ES2647223T3 (enExample)
IL (1) IL222244A0 (enExample)
MX (1) MX2012011938A (enExample)
NZ (1) NZ603040A (enExample)
SG (2) SG184430A1 (enExample)
WO (1) WO2011127538A1 (enExample)
ZA (1) ZA201207696B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2909057C (en) 2013-04-12 2022-03-22 Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
BR112016029942A2 (pt) 2014-06-20 2017-08-22 Aviragen Therapeutics Inc composto, forma de base livre cristalina anidra, composição farmacêutica, método para fabricação de uma forma de base livre cristalina, método de tratamento de uma infecção viral, método de tratar, aliviar, prevenir ou reduzir os sintomas ou exacerbações de asma ou doença pulmonar obstrutiva crônica e método de tratamento de doença mão, pé e boca
WO2024192151A2 (en) * 2023-03-13 2024-09-19 Altesa BioSciences, Inc. Method of dosing vapendavir to treat enterovirus infections

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR213700A0 (en) * 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
CA2475971A1 (en) * 2002-02-14 2003-08-21 Viropharma Incorporated Methods of reducing rhinovirus contagion and related compositions
ATE399549T1 (de) * 2003-02-21 2008-07-15 Apodemus Ab Behandlung von durch das ljungan-virus ausgelösten erkrankungen durch verwendung von pleconaril
US9308199B2 (en) * 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
US20060069124A1 (en) * 2004-09-07 2006-03-30 Rao P S Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
NZ590286A (en) * 2008-05-27 2011-08-26 Biota Scient Management Phosphate and sulphate salts of 6-{ 2-[1-(6-methyl-3-pyrazinyl)-4-piperidinyl]ethoxy} -3-ethoxy-1,2-benzisoxazole
TW201016215A (en) * 2008-07-17 2010-05-01 Schering Corp Compositions and uses of antiviral active pharmaceutical agents

Similar Documents

Publication Publication Date Title
JP2012520866A5 (enExample)
JP2011522816A5 (enExample)
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2013541583A5 (enExample)
JP2008044951A5 (enExample)
JP2014515373A5 (enExample)
JP2016501865A5 (enExample)
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
JP2013522212A5 (enExample)
JP2014528901A5 (enExample)
EP2216024A3 (en) Use of Ranolazine for the treatment of cardiovascular diseases
JP2012515184A5 (enExample)
JP2012502909A5 (enExample)
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2013518124A5 (enExample)
JP2018513188A5 (enExample)
JP2013536837A5 (enExample)
JP2016507500A5 (enExample)
JP2013523844A5 (enExample)
JP2011500589A5 (enExample)
JP2010517992A5 (enExample)
JP2020500930A5 (enExample)
JP2009534367A5 (enExample)
JP2012502105A5 (enExample)
CN108472375A (zh) 中重度流感的治疗方法